Narcolepsy Market, By Type (Type 1 and Type 2 Narcolepsy), By Treatment (Antidepressants, Stimulants, Sodium oxybate and Others), By Diagnosis (Poysomnogram, Multiple sleep latency test and Others), By End Users (Hospitals, Retail Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI471821 | Publish Date: August 2023 | No. of Pages: 168

Global Narcolepsy Market Companies

  • BIOPROJET
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Shire
  • Shionogi Inc.
  • Ligand Pharmaceuticals, Inc.

Recent News:

  • In March 2022, Axsome Therapeutics Inc. and Jazz Pharmaceuticals signed felony agreement for Axsome Therapeutics Inc. to received Sunosi (solriamfetol), is a medicinal drug indicated to enhance wakefulness in grownup sufferers with immoderate daylight sleepiness because of narcolepsy or obstructive sleep apnea.
  • In January 2021, Harmony Biosciences introduced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pitolisant, a medicinal drug indicated for the remedy of cataplexy and immoderate daylight sleepiness in sufferers with narcolepsy.
  • In 2020, Jazz Pharmaceuticals received Cavion, Inc., a clinical-degree biotechnology employer targeted on growing treatment plans for neurological diseases, inclusive of narcolepsy. This acquisition improved Jazz Pharmaceuticals` pipeline of capability narcolepsy treatments.